2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors

Description of the invention

The present invention relates to 2-phenyl-substituted imidazotriazinone, vardenafil, which is 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5 , 1-f] [1,2,4] -triazin-4-one of the formula I and its salts and hydrates, a method of its preparation and its use for the preparation of medicaments, especially agents active against erectile dysfunction.

The published patent DE 2811780 describes imidazotriazines as bronchodilators with spasmolytic activity and inhibitory activity against phosphodiesterases metabolizing cyclic adenosine monophosphate (cAMP-PDE, Beavo nomenclature: PDE-III and PDE-IV). The inhibitory effect on phosphodiesterases that metabolize guanosine monophosphate (cGMP-PDE, nomenclature according to Beavo and Reifsnyder (Trends in Pharmacol. Sci. 11, 150-155, 1990) PDE-I, PDE-II and PDE-V) is not described. No compounds with a sulphonamide group in the aryl group in the 2-position are claimed. In addition, patents FR 2213058, CH 594671, DE 2255172, DE 2364076 and EP 0009384 describe imidazotriazinones which do not have a substituted aryl group in the 2-position and which are also described in are as bronchodilators with cAMP-PDE inhibitory activity.

In WO94 / 28902, pyrazolopyrimidinones are described which are suitable for the treatment of impotence.

The compounds of the invention are potent inhibitors of one or more phosphodiesterases that metabolize cyclic guanosine 3 ', 5'-monophosphate (cGMP-PDE). According to the nomenclature of Beavo and Reifsnyder (Trends in Pharmacol. Sci. 11, 150-155, 1990), these are phosphodiesterase isoenzymes PDE-I, PDE-II and PDE-V.

Elevation of cGMP may lead to therapeutic, anti-aggregation, anticoagulant, antiproliferative, anti-vasoconstriction, vasodilator, sodium-excreting and diuretic effects. It may also affect the short- and long-term modulation of vascular and cardiac inotropy, the heart rate and the cardiac conduction of the stimulus (JC Stoclet, T. Keravis, N. Komas and C. Kugnier, Exp. Opin. Invest. Drugs (1995), 4 (11), 1081-1100).

The present invention relates to a 2-phenyl-substituted imidazotriazinone being 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5,1-f] [1,2,4] triazin-4-one of the formula I and its salts and hydrates.

2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [1,2,4 ] a triazin-4-one of formula Ia.

Furthermore, 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [1,2 4] a triazin-4-one of formula Ib.

Also particularly preferred is 2- [2-ethoxy-5- (4-ethyl-piperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [1,2, 4] a triazin-4-one of the formula Ic.

The substance according to the invention may also be in the form of a salt. In the context of the invention, physiologically acceptable salts are preferred.

Physiologically acceptable salts can be salts of the compounds of the invention with inorganic or organic acids. Salts with inorganic acids, such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid, or salts with organic carboxylic or sulfonic acids, such as, for example, acetic acid, maleic acid, fumaric acid, malic acid, citric acid are preferred. , tartaric acid, lactic acid, benzoic acid or methanesulfonic acid, ethanesulfonic acid, phenylsulfonic acid, toluenesulfonic acid, or naphthalenedisulfonic acid.

Physiologically acceptable salts are also the metal or ammonium salts of the compounds according to the invention.

Particularly preferred are, for example, sodium, potassium, magnesium or calcium salts and ammonium salts derived from ammonia or organic amines, such as, for example, ethylamine, di or triethylamine, di or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine. or 2-phenylethylamine.

The invention further relates to a process for the preparation of compounds according to the invention of formula I, optionally in the form of their salts, hydrates and isomeric forms, wherein first a compound of general formula II in which L is a straight or branched alkyl group with up to 4 carbon atoms is subjected to reacting with a compound of formula III, and then the obtained compound of formula IV,

The mixture is reacted with chlorosulfonic acid to give a compound of formula V, which is then reacted with an amine of formula VI in an inert solvent.

Preferably, the compound obtained is crystallized from water or in an aqueous solvent.

As solvents for the individual steps, known organic solvents which do not vary under the reaction conditions can be used. Preference is given to ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethane, dichloroethane. trichlorethylene or chlorobenzene or ethyl acetate, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the solvents mentioned. Ethanol is used particularly preferably in the first stage and dichloroethane in the second stage.

The reaction temperature can be varied over a wide range. In general, the reaction is carried out at a temperature of -20 ° C to 200 ° C, preferably 0-70 ° C.

The steps of the process according to the invention are generally carried out under atmospheric pressure. The process can also be carried out under elevated or reduced pressure (e.g. in the range of 0.5-5 bar).

The reaction to obtain compounds of the general formula V is carried out at a temperature from 0 ° C to room temperature and normal pressure.

The reaction with the amine of formula VI is carried out in one of the abovementioned chlorinated hydrocarbons, preferably in dichloromethane.

The reaction temperature can be varied over a wide range. In general, the process is carried out at a temperature of -20 ° C to 200 ° C, preferably 0 ° C to room temperature.

The reaction is generally carried out under normal pressure. However, the process can also be carried out at elevated or reduced pressure (e.g. in the range 0.5-5x10 kPa).

The compounds of general formula II are prepared by converting compounds of general formula VII in which T is halogen, preferably chlorine, first by reaction with a compound of formula VIII in inert solvents, optionally in the presence of a base and trimethylsilyl chloride, a compound of formula IX, which is then reacted with a compound of formula X, wherein L is as defined above, in inert solvents, optionally in the presence of a base.

Solvents used in the individual process steps are known organic solvents which do not change under the reaction conditions. Preference is given to ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachethylene methane, dichloromethane, dichloromethane. , trichlorethylene or chlorobenzene, or ethyl acetate, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone, dimethoxyethane or pyridine. It is also possible to use mixtures of the solvents mentioned. It is particularly preferred to use dichloromethane in the first step and a mixture of tetrahydrofuran and pyridine in the second step.

The bases used are generally alkali metal hydrides or alkoxides, such as, for example, sodium hydride or potassium t-butoxide, or cyclic amines, such as, for example, piperidine, pyridine, dimethylaminopyridine or C1-C.₄-alkylamines such as, for example, triethylamine. Preference is given to using triethylamine, pyridine and / or dimethylaminopyridine.

The base is generally used in an amount of 1 to 4 moles, preferably 1.2 to 3 moles, based on each mole of the compound of the formula X.

Generally, the reaction temperature can be varied over a wide range. Typically the process is carried out at a temperature of -20 ° C to 200 ° C, preferably 0-100 ° C.

Compounds of formulas VII, VIII, IX and X are known.

Compound: Formula III can be prepared by reacting a compound of formula XI with ammonium chloride in toluene and in the presence of trimethylaluminum in hexane at -20 ° C to room temperature, preferably at 0 ° C and normal pressure , and the resulting amidine, optionally in situ, is reacted with hydrazine hydrate.

Compounds of formulas IV and XI are known.

The compound of formula V is new, but can be prepared from a compound of general formula IV according to Publication Organikum, VEB Deutscher Verlag der Wissenschaften, Berlin 1974, pp. 338-339.

The invention further relates to the use of 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5,1-f] [1,2, 4] triazin-4-one of the formula I and its salts, optionally in the form of hydrates, for the preparation of medicaments for the treatment of erectile dysfunction.

PL 194 801 B1

2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5,1-f] [1,2,

4] triazin-4-one of the formula I and optionally its salts and isomeric forms, optionally in the form of hydrates, can be used as medicaments or converted into medicaments further comprising a pharmacologically acceptable excipient.

The compound of the invention of the general formula I exhibits an unpredictable, valuable range of pharmacological activities.

This compound inhibits one or more cGMP-metabolizing phosphodiesterases (PDE I, PDE II and PDE V). This leads to an increase in cGMP. The differential expression of phosphodiesterases in various cells, tissues and organs, as well as the differential subcellular localization of these enzymes, in combination with the selective inhibitors of the invention make it possible to selectively target various processes regulated by cGMP.

In addition, the compound of the invention enhances the action of substances such as, for example, EDRF (endothelium derived relaxing factor), ANP (atrial natriuretic peptide), nitro vasodilators and any other substances that otherwise than phosphodiesterase inhibitors increase the concentration of cGMP.

It can therefore be used in medicaments for the treatment of cardiovascular diseases, such as, for example, the treatment of hypertension, neuronal hypertension, stable and unstable angina, peripheral and cardiac disorders, arrhythmias, for the treatment of thrombotic and ischemic diseases such as myocardial infarction. , stroke, transient and ischemic attacks, angina, disruption of peripheral blood flow, prevention of restenosis after clot dissolution therapy, percutaneous transluminal angioplasty (PTA), percutaneous transluminal coronary artery (PTCA) and bypass surgery. Moreover, this relationship may be important in the case of cerebrovascular diseases. The smooth muscle relaxant effect makes the compound suitable for the treatment of urogenital diseases such as prostate hypertrophy, urinary incontinence, and especially for the treatment of erectile dysfunction and female sexual dysfunction.

Phosphodiesterase (PDE) activity

CGMP PDE II stimulatory, cGMP PDE III inhibitory, and cAMP-specific PDE IV are isolated from the myocardium of pigs or steers. PDE I stimulating Ca²⁺-calmodulin is isolated from a porcine aorta, a porcine brain or preferably from a bull aorta. cGMP-specific PDE V is obtained from porcine small intestine, porcine aorta, human platelets and preferably bovine aorta. Purification is done by MonoQ anion exchange chromatography^R Pharmacia essentially by the method of M. Hoey and Miles D. Houslay, Biochemical Pharmacology, Vol. 40, 193-202 (1990) and C. Lugman et al., Biochemical Pharmacology Vol. 35, 1743-1751 (1986).

Enzyme activity determination is carried out on 100 ml test samples in 20 mM Tris / HCl buffer pH 7.5 containing 5 mM MgCl₂, 0.1 mg / ml bovine serum albumin and 800 Bq ³HcAMP or ³HcGMP. The final concentration of the corresponding nucleotides is 10⁶ mol / liter. The reaction is started by adding the enzyme, the amount of enzyme being measured such that, during an incubation time of 30 minutes, about 50% of the substrate is converted. For testing PDE III stimulating cGMP as substrate is used³HcAMP and 106 mol / liter of unlabeled cGMP is added to the sample. For testing PDE I of Ca2 + -calmodulin dependent, 1 mM CaCl2 and 0.1 mM calmodulin are added to the reaction sample. The reaction is stopped by adding 100 ml of acetonitrile containing 1 mM cAMP and 1 mM AMP. A 100 ml reaction sample is separated by HPLC and the cleavage products are quantified "Online" using a flow scintillation counter. The concentration of the substance is measured at which the reaction rate is reduced by 50%. Additionally, the "phosphodiesterase enzyme test [³H] cAMP-SPA "and" phosphodiesterase enzyme test [³H] cGMPSPA "from Amersham Life Science. The testing is carried out in accordance with the manufacturer's prescription for use. The test [³H] cAMP-SPA, with 10 being added to the test sample^S.M cGMP for enzyme activation. For the measurement of PDE I, 10 is added to the test sample⁷ M calmodulin and 1mM CaCl2. PDE V is measured using the test^[3H.^]cGMP^-SPA.

PL 194 801 B1

Inhibition of phosphodiesterases in vitro

<td>Example no</td><td>PDE I IC50 [nM]</td><td>PDE II IC50 [nM]</td><td>PDE V IC50 [nM]</td>

<td> 1</td><td> 200</td><td> &gt;1000</td><td> 2</td>

<td> 2</td><td> 200</td><td> &gt;1000</td><td> 2</td>

In general, inhibition of one or more of these phosphodiesterases leads to an increase in cGMP levels. Therefore, these compounds are of interest for all therapies in which an elevated cGMP concentration may be considered therapeutic.

The study of the cardiovascular effect is performed in SH rats and dogs. The substances are administered intravenously or orally.

The study of the erectile effect is carried out on sleepless rabbits [H. Naganuma, T. Egashira, J. Fuji, Clinical and Experimental Pharmacology and Physiology 20, 177-183 (1993)]. The substances are administered intravenously, orally or parenterally.

The new active ingredient and its physiologically acceptable salts (e.g. hydrochlorides, maleates or lactates) can be converted in a known manner into conventional preparations such as tablets, dragées, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using neutral, non-toxic pharmaceutically acceptable carriers or solvents. The therapeutically active compound should be present in each case in a concentration of about 0.5-90% by weight of the total mixture, i.e. in an amount sufficient to achieve the dosage range given.

The formulations are obtained, for example, by mixing the active ingredient with solvents and / or carriers, and / or with the use of emulsifiers and / or dispersants, whereby, for example, when using water as an extender, organic solvents can optionally be used as auxiliary solvents.

Administration is carried out in a manner known per se, preferably orally, percutaneously or parenterally, e.g. sublingually, buccally, intravenously, nasally, rectally or by inhalation.

For administration to humans by oral administration, the dose is preferably 0.001-50 mg / kg, especially 0.01-20 mg / kg. In the case of parenteral administration, such as via the mucous membranes, intranasally, buccally, by inhalation, the dose is preferably 0.001-0.5 mg / kg.

Nevertheless, it may be desirable to deviate from the amounts mentioned, namely depending on the body weight or the type of administration route, the individual behavior with the medicament, the type of preparation and the time or time interval over which administration takes place. Thus, in some cases it may be sufficient to use less than the above-mentioned minimum amounts, while in other cases the above-mentioned upper limit must be exceeded. When larger amounts are administered, it may be advisable to split this amount into several unit doses throughout the day.

The compound of the invention is also suitable for veterinary use. For veterinary use, these compounds, or non-toxic salts thereof, can be administered in the form of a suitable preparation in accordance with generally accepted veterinary practice. The veterinarian may determine the method of administration and dosage depending on the type of animal being treated.

The following examples demonstrate the preparation of compounds of the invention.

Example 1. 2- [2-Ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [1,2 , 4] a triazin-4-one of formula I.

470 mg (1.14 mmol) 4-ethoxy-3- (5-methyl-4-oxo-7-propyl-3,4-dihydro-imidazo [5,1-f] [1,2,4] triazine acid chloride -2-yl) -benzenesulfonic acid is dissolved in 20 ml of dichloromethane and cooled to 0 ° C. 390 mg (3.42 mmol) of N-ethylpiperazine are added and the reaction mixture is stirred overnight at room temperature. It is then diluted with dichloromethane, the organic phase is washed twice with water, dried over sodium sulphate and the solvent is eliminated in vacuo. After crystallization from ether, 370 mg (66%) of a colorless solid are obtained.

200 MH^{from 1}H.^-NMR ⁽CDCl₃^): 1.01, t, 3H; 1.59, t, 3H; 1.88, hexet, 2H; 2.42, quartet, 2H; 2.56 m^, 4H; 2.63, s, 3H; 3.00, t, 2H; 3.10, m, 4H; 4.33, quartet, 2H; 7.17, d, 1H; 7.88, dd, 1H; 8.44, d, 1H; 9.75, s, 1H.

PL 194 801 B1

Example 2. 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5,1-f] [1, 2,4] a triazin-4-one of the formula Ia.

0.35 g (0.712 mmol) of 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [1 The, 2,4] triazin-4-one is suspended in 8 ml of ether and sufficient dichloromethane is added until a homogeneous solution is obtained. 0.8 ml of 1M HCl solution in ether are added, the mixture is stirred for 20 minutes at room temperature and suction filtered. 372 mg (99%) of 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [hydrochloride] hydrochloride are obtained. 1,2,4] triazin-4-one.

200 MH^{from 1}H.^-NMR ⁽DMSO^-d_s⁾: 0.96, t, 3H; 1.22, t, 3H; 1.36, t, 3H; 1.82, sextet 2H; 2^,61^, s^, 3H; 2.88, m, 2H; 3.08, m, 6H; 3.50, m, 2H; 3.70, m, 2H; 4.25, quartet, 2H; 7.48, d, 1H; 7.95, m, 2H; 11.42, s, 1H; 12.45, s, 1H.

Example 3. 2- [2-Ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-fj [1] hydrochloride trihydrate, 2,4] a triazin-4-one of formula Ib.

The free base of Example 1 is crystallized from a mixture of an organic solvent and dilute aqueous hydrochloric acid to give the hydrochloride trihydrate.

Melting point: 218 ° C

Water content: 9.4% (K. Fischer)

Chloride content: 6.1%

Example 4 2- [2-Ethoxy-5- (4-ethylpieperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5,1-f | [1, 2,4] triazin-4-one of the formula Ic.

0.35 g (0.712 mmol) of 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [1 The, 2,4] triazin-4-one is suspended in 8 ml of ether and dichloromethane is added in such an amount to form a homogeneous solution. 2.4 ml of a 1M solution of HCl in ether are added, the mixture is stirred for 20 minutes at room temperature and suction filtered. 372 mg (99%) of 2- [2-ethoxy-5- (4-ethylpiperazine-1-sulfonyl) -phenyl] -5-methyl-7-propyl-3H-imidazo [5.1-f] [dihydrochloride] are obtained. 1,2,4] -triazin-4-one.

200 MH^{from 1}H.^-NMR ⁽DMSO^-d^6,): 0.96, t, 3H^; 1.22, t, 3H^; 1.36, t, 3H^; 1.82, sextet 2H^; 2.61, p^,3H; 2.88, m, 2H; 3.08, m, 6H; 3.50, m, 2H; 3.70, m, 2H; 4.25, quartet, 2H; 7.48, d, 1H; 7.95, m, 2H; 11.42, s, 1H; 12.45, s, 1H.